Penserra Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Penserra Capital Management’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-16,705	Closed	-$245K	–	1063
2020 Q2	$245K	Buy	+16,705	New	+$170K	0.01%	458
2017 Q1	–	Sell	-3,243	Closed	-$39K	–	896
2016 Q4	$39K	Buy	3,243 +633	+24%	+$7.52K	﹤0.01%	419
2016 Q3	$30K	Buy	2,610 +1,044	+67%	+$10.1K	﹤0.01%	428
2016 Q2	$14K	Buy	1,566 +546	+54%	+$3.74K	﹤0.01%	516
2016 Q1	$5	Buy	1,020 +472	+86%	+$2.63K	﹤0.01%	861
2015 Q4	$4K	Buy	+548	New	+$4.21K	﹤0.01%	900

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Penserra Capital Management's GNMK Position: Q3 2020 in Review

Penserra Capital Management sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2020, closing a stake of 16,705 shares — an estimated $245K sold.

Penserra Capital Management first reported a position in GNMK in Q4 2015 and held it in 6 quarters. The position peaked at $245K in Q2 2020. 163 funds tracked by Wall St. Rank hold GNMK as of Q3 2020.

Penserra Capital Management reported no remaining GenMark Diagnostics, Inc position as of Q3 2020 after selling out during the quarter.
Penserra Capital Management sold 16,705 GenMark Diagnostics, Inc shares in Q3 2020, an estimated $245K.
Penserra Capital Management first reported a position in GenMark Diagnostics, Inc in Q4 2015 and held it in 6 quarters.
Penserra Capital Management's GenMark Diagnostics, Inc position peaked at $245K in Q2 2020.
163 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2020.

Based on Penserra Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.